Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
Haemophilus influenzae type B
Japanese encephalitis
SAGE documentation
GRADE table
Clear all
Type of publications
SAGE documentation
(12)
Topics
GRADE table
(12)
Available to download in languages
English (EN)
(12)
Regions
Countries
Diseases
Haemophilus influenzae type B
(3)
Japanese encephalitis
(9)
Cholera
(1)
COVID-19
(2)
Dengue
(6)
Diphtheria
(1)
Hepatitis A
(6)
Human papillomavirus (HPV)
(9)
Influenza
(11)
Measles
(6)
Meningococcal disease
(4)
Pertussis
(2)
Rubella
(1)
Typhoid
(2)
Vaccine topics
Target population
Publication date
2015
(9)
2013
(3)
12 results found
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live attenuated JE vaccine?
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with live recombinant JE vaccine?
2015
∙
SAGE
Is there a need for a booster dose following immunization with one dose of live attenuated JE vaccine in individuals living in JE-endemic areas?
2015
∙
SAGE
Is there a need for a booster dose following immunization with a single dose of live recombinant JE vaccine in vaccinees living in JE-endemic areas?
2015
∙
SAGE
Is there a need for a booster dose following immunization with the primary series of inactivated Vero cell-derived JE vaccine in individuals living in JE-endemic areas?
2015
∙
SAGE
What is the effectiveness of inactivated Vero cell-derived JE vaccine in preventing JE disease in vaccinees living in JE-endemic areas?
2015
∙
SAGE
What is the effectiveness of live attenuated JE vaccine in preventing JE disease in vaccinees living in JE-endemic areas?
2015
∙
SAGE
What is the effectiveness of live recombinant JE vaccine in preventing JE disease in vaccinees living in JE-endemic areas?
2015
∙
SAGE
What is the risk of serious adverse events following vaccination with inactivated Vero cell-derived JE vaccine?
2013
∙
SAGE
Hib vaccination schedules: three primary doses plus one booster dose versus two primary doses plus one booster dose
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register